| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $8,999,984 | 1 | 2 |
Sells | $42,201,816 | 42 | 98 |
| Heron Patrick J | director | 1 | $9M | 0 | $0 | $9M |
| Quan Joanne | CHIEF MEDICAL OFFICER | 0 | $0 | 3 | $1.46M | $-1.46M |
| Ramasastry Saira | director | 0 | $0 | 8 | $1.92M | $-1.92M |
| Radovich Peter | PRESIDENT AND COO | 0 | $0 | 4 | $2.32M | $-2.32M |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 0 | $0 | 7 | $3.56M | $-3.56M |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | 0 | $0 | 9 | $5.55M | $-5.55M |
| GREY MICHAEL G | director | 0 | $0 | 3 | $11.1M | $-11.1M |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | 0 | $0 | 8 | $16.29M | $-16.29M |
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its …
Over the last 12 months, insiders at Mirum Pharmaceuticals, Inc. have bought $9M and sold $42.2M worth of Mirum Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Mirum Pharmaceuticals, Inc. have bought $2.83M and sold $13.74M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $9M.
The last purchase of 131,425 shares for transaction amount of $9M was made by Heron Patrick J (director) on 2026‑01‑23.
| 2026-09-14 | Sale | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 9,943 0.016% | $98.37 | $978,093 | -11.61% | |
| 2026-09-02 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 658 0.0011% | $100.00 | $65,800 | -13.84% | |
| 2026-09-01 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 30,000 0.0494% | $98.68 | $2.96M | -12.51% | |
| 2026-08-18 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 40,000 0.065% | $100.00 | $4M | -12.12% | |
| 2026-08-11 | Sale | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 6,001 0.01% | $99.90 | $599,510 | -8.68% | |
| 2026-08-10 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 20,000 0.0316% | $98.92 | $1.98M | -8.26% | |
| 2026-08-03 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 1,840 0.0031% | $105.29 | $193,734 | -12.04% | |
| 2026-07-06 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 20,000 0.04% | $122.27 | $2.45M | -19.55% | |
| 2026-07-06 | Sale | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 5,000 0.01% | $122.25 | $611,273 | -19.55% | |
| 2026-07-01 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 2,721 0.0054% | $120.00 | $326,520 | -18.46% | |
| 2026-06-17 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 2,594 0.0052% | $101.95 | $264,458 | -3.37% | |
| 2026-06-08 | Sale | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 5,000 0.01% | $93.82 | $469,077 | +5.53% | |
| 2026-06-01 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 30,000 0.0595% | $95.84 | $2.88M | +2.17% | |
| 2026-06-01 | Sale | Ramasastry Saira | director | 3,977 0.0082% | $100.00 | $397,700 | +2.17% | |
| 2026-05-15 | Sale | Ramasastry Saira | director | 2,000 0.0043% | $109.47 | $218,940 | -3.68% | |
| 2026-04-15 | Sale | Ramasastry Saira | director | 2,000 0.004% | $96.90 | $193,800 | +1.99% | |
| 2026-03-16 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 40,985 0.0811% | $91.98 | $3.77M | +5.06% | |
| 2026-03-16 | Sale | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 7,287 0.0144% | $91.98 | $670,243 | +5.06% | |
| 2026-03-16 | Sale | Radovich Peter | PRESIDENT AND COO | 16,515 0.0327% | $91.98 | $1.52M | +5.06% | |
| 2026-03-16 | Sale | Quan Joanne | CHIEF MEDICAL OFFICER | 7,287 0.0144% | $91.98 | $670,243 | +5.06% |
| Heron Patrick J | director | 459010 0.7069% | $39.95M | 16 | 0 | +31.91% |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | 194440 0.2995% | $16.92M | 4 | 20 | +41.16% |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 44745 0.0689% | $3.89M | 3 | 9 | +37.06% |
| BARRIS PETER J | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| MOTT DAVID M | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| MAKOWER JOSHUA | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| SANDELL SCOTT D | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| BASKETT FOREST | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| Walker Paul Edward | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| Sonsini Peter W. | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| Florence Anthony A. Jr. | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| Behbahani Ali | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| Makhzoumi Mohamad | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| New Enterprise Associates 16, L.P. | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| Chang Carmen | 10 percent owner | 4186243 6.4471% | $364.33M | 1 | 0 | +5.09% |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 3566912 5.4933% | $310.43M | 1 | 0 | +5.09% |
| Novo Holdings A/S | 10 percent owner | 2445147 3.7657% | $212.8M | 1 | 0 | +5.09% |
| O'Donnell Niall | director | 1621118 2.4966% | $141.09M | 1 | 3 | +5.09% |
| Longpre Lara | CHIEF DEVELOPMENT OFFICER | 104407 0.1608% | $9.09M | 1 | 5 | +63.65% |
| Tucker Edwin Jonathan | Chief Medical Officer | 45768 0.0705% | $3.98M | 2 | 1 | +71.87% |
| Vig Pamela | CHIEF SCIENTIFIC OFFICER | 27406 0.0422% | $2.39M | 1 | 6 | +53.04% |
| Clements Ian | Chief Financial Officer | 18561 0.0286% | $1.62M | 4 | 1 | +42.68% |
| Brege Laura | director | 15703 0.0242% | $1.37M | 1 | 1 | +63.65% |
| Fischer Laurent | director | 6750 0.0104% | $587,452.50 | 5 | 0 | +66.98% |
| Flynn James E | 10 percent owner | 0 0% | $0 | 1 | 4 | +5.09% |
$67,892,722 | 138 | 28.28% | $6.25B | |
Mirum Pharmaceuticals, Inc. (MIRM) | $224,662,742 | 52 | 32.03% | $5.65B |
$613,304,943 | 46 | 11.85% | $6.22B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 167 | +58.39% | 9M | +15.42% |
| Decreased Positions | 123 | -43.01% | 4M | -7.69% |
| New Positions | 64 | New | 3M | New |
| Sold Out Positions | 43 | Sold Out | 1M | Sold Out |
| Total Postitions | 330 | +15.38% | 61M | +7.73% |
| Frazier Life Sciences Management, L.P. | $530,495.00 | 13.07% | 6.8M | 0 | 0% | 2025-09-30 |
| Janus Henderson Group Plc | $390,162.00 | 9.61% | 5M | -238,691 | -4.56% | 2025-09-30 |
| Blackrock, Inc. | $281,242.00 | 6.93% | 3.6M | +25,343 | +0.71% | 2025-09-30 |
| Vanguard Group Inc | $198,717.00 | 4.89% | 2.55M | -19,500 | -0.76% | 2025-09-30 |
| Eventide Asset Management, Llc | $196,936.00 | 4.85% | 2.52M | -114,922 | -4.36% | 2025-09-30 |
| Bvf Inc/Il | $116,737.00 | 2.88% | 1.5M | -1M | -45.85% | 2025-09-30 |
| State Street Corp | $105,153.00 | 2.59% | 1.35M | -28,724 | -2.09% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $100,186.00 | 2.47% | 1.28M | -133,927 | -9.45% | 2025-09-30 |
| Novo Holdings A/S | $98,683.00 | 2.43% | 1.26M | -236,027 | -15.73% | 2025-09-30 |
| Tang Capital Management Llc | $96,497.00 | 2.38% | 1.24M | 0 | 0% | 2025-09-30 |